期刊
EXPERT OPINION ON THERAPEUTIC TARGETS
卷 -, 期 -, 页码 -出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14728222.2023.2258280
关键词
Galectin-3; liver disease; inflammation; fibrosis; galectin-3 inhibitor
The incidence of liver diseases is increasing worldwide, but there are limited therapeutic options for managing chronic inflammation and fibrosis, which are the main causes of morbidity and mortality in liver diseases. Galectin 3 (Gal-3) is a protein involved in fibrosis in multiple organs, and several Gal-3 inhibitors are currently being developed for clinical use.
IntroductionThe rising incidence of liver diseases is a worldwide healthcare concern. However, the therapeutic options to manage chronic inflammation and fibrosis, the processes at the basis of morbidity and mortality of liver diseases, are very limited. Galectin 3 (Gal-3) is a protein implicated in fibrosis in multiple organs. Several Gal-3 inhibitors are currently in clinical development.Areas coveredThis review describes our current understanding of the role of Gal-3 in chronic liver diseases, with special emphasis on fibrosis. Also, we review therapeutic advances based on Gal-3 inhibition, describing drug properties and their current status in clinical research.Expert opinionCurrently, the known effects of Gal-3 point to a direct activation of the NLRP3 inflammasome leading to its activation in liver macrophages and activated macrophages play a key role in tissue fibrogenesis. However, more research is needed to elucidate the role of Gal-3 in the different activation pathways, dissecting the intracellular and extracellular mechanisms of Gal-3, and its role in pathogenesis. Gal-3 could be a target for early therapy of numerous hepatic diseases and, given the lack of therapeutic options for liver fibrosis, there is a strong pharmacologic potential for Gal-3-based therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据